Dr. Derwenskus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 The Vanderbilt Clinic
Nashville, TN 37232Phone+1 615-936-2000
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Neurology, 2000 - 2003
McGaw Medical Center of Northwestern UniversityInternship, Internal Medicine, 1999 - 2000
Des Moines University College of Osteopathic MedicineClass of 1998
Certifications & Licensure
TN State License 2015 - 2026
KY State License 2020 - 2025
IL State License 1999 - 2017
NY State License 2003 - 2006
OH State License 2000 - 2003
MI State License 1998 - 1999- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Start of enrollment: 2011 Sep 08
- Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis Start of enrollment: 2011 Mar 01
- Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Start of enrollment: 2013 Nov 01
Publications & Presentations
PubMed
- Improving the Detection of Myelin Integrity in Multiple Sclerosis Using Selective Inversion Recovery for MRI With Quantitative Magnetization Transfer.Ahmad A Toubasi, Dhairya A Lakhani, Gary Cutter, Caroline Gheen, Taegan Vinarsky
Journal of Magnetic Resonance Imaging. 2024-12-10 - 3 citationsParamagnetic rim lesions and the central vein sign: Characterizing multiple sclerosis imaging markers.Margareta A Clarke, Rachael Cheek, Habeeb F Kazimuddin, Bryan Hernandez, Reece Clarke
Journal of Neuroimaging. 2023-11-29 - 22 citationsPregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.Jiwon Oh, Anat Achiron, Elisabeth Gulowsen Celius, Christina D. Chambers, Joy Derwenskus
Multiple Sclerosis and Related Disorders. 2020-08-01
Press Mentions
Multiple Sclerosis Patients See Signs of Increased SupportAugust 13th, 2021- Nashville Ranked as Migraine HotspotNovember 13th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
